Wednesday, April 23, 2014

Alpha Cancer to test oncology game changer

Alpha Cancer to test oncology game changer

March 11, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=HJr8cGE2eVs’]

Tweet Closely held Alpha Cancer Technologies, which is going public in a reverse takeover of Bradmer Pharmaceuticals (TSX-V:BMR-H), plans to begin testing patients with ovarian cancer this year with its drug candidate, ACT-901, which features a novel targeted drug delivery platform. BioTuesdays.com had an opportunity to interview the company’s founder & CEO, Dr. Igor Sherman, […]

Advaxis readies cervical cancer pivotal trial

Advaxis readies cervical cancer pivotal trial

February 25, 2014 by · Leave a Comment 

Tweet Advaxis (NASDAQ:ADXS) hopes to begin a registration trial before the end of the year with its next-generation immunotherapy, ADXS-HPV, for the treatment of invasive cervical cancer. “We are pleased with the encouraging results of our Phase 2 study, which supports a continuing path towards registration for our lead product candidate,” CEO Daniel O’Connor says […]

OncoGenex’s OGX-427 drug gaining investor attention

OncoGenex’s OGX-427 drug gaining investor attention

March 26, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=3q82Rl_y8Rc’]

Tweet Even though OncoGenex Pharmaceuticals (NASDAQ:OGXI) and its pivotal programs with lead oncology candidate, custirsen, are being closely followed, investors are beginning to notice the company’s second generation antisense drug, OGX-427. “We have data in bladder and prostate cancer with OGX-427 that, we believe, indicates clinical activity,” co-founder, president and CEO, Scott Cormack, says in […]

MDxHealth strengthens position in epigenetics testing

MDxHealth strengthens position in epigenetics testing

March 5, 2013 by · Leave a Comment 

Tweet After launching a breakthrough epigenetics diagnostic for prostate cancer in the U.S. last May, Belgium-based MDxHealth (NYSE Euronet:MDXH), with U.S. headquarters in Irvine, Calif., continues to demonstrate strong scientific data for its ConfirmMDx molecular test and its economic benefits. “As many as one-in-four men are misdiagnosed with a false-negative biopsy result but have hidden […]

Novadaq highlights game changer for the OR

Novadaq highlights game changer for the OR

October 16, 2012 by · Leave a Comment 

Tweet With adoption of its SPY imaging technologies growing in operating rooms across North America, Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has embarked on a long-term growth plan to image nerves and cancer cells with tissue-binding reagents that could represent a paradigm shift in the OR. “The future of the installed base of SPY technologies will include […]

Soricimed treats first patient in Phase 1 trial with SOR-C13

Soricimed treats first patient in Phase 1 trial with SOR-C13

August 14, 2012 by · Leave a Comment 

http://www.youtube.com/watch?v=WrMIAU0Tkkk’]

Tweet Closely held Soricimed Biopharma has treated the first patient with its anti-cancer agent SOR-C13 in a Phase 1 clinical trial at the Juravinski Cancer Centre in Hamilton, Ont. The trial, which will take place at cancer centers in Canada and the U.S., is designed to assess safety and tolerability in patients with advanced cancer […]

Soricimed gaining media awareness

Soricimed gaining media awareness

August 10, 2012 by · Leave a Comment 

Tweet Closely held Soricimed Biopharma continued to gain media attention this week with its novel drug candidate based on the paralytic venom in the saliva of the tiny North American short-tailed shrew, which is being developed as a treatment for ovarian, breast and prostate cancers in humans. In a front-page article in the Globe and […]

NY approval of ColonSentry opens door for GeneNews

NY approval of ColonSentry opens door for GeneNews

February 28, 2012 by · Leave a Comment 

http://www.youtube.com/watch?v=0mzb8_cDcEg&context=C356b099ADOEgsToPDskJ0iEp5__5c0FjC8xsLwFBH’]

Tweet Last week’s approval by New York State of GeneNews’ (TSX:GEN) ColonSentry molecular diagnostic test to determine a person’s risk of having colorectal cancer opens the door to the entire U.S. market and other jurisdictions around the world for the simple blood test. “Our lead product has now been approved by the most stringent level […]

OncoVista gives personalized medicine a twist

OncoVista gives personalized medicine a twist

May 10, 2011 by · 2 Comments 

Tweet Taking personalized medicine to the next level, Alexander Weis likes to say that OncoVista Innovative Therapies (OTCBB:OVIT) is using a “targeted” approach to preselect and treat cancer patients with drugs that are more effective and less toxic and that can improve their quality of life. “I don’t believe in one-size-fits-all treatments when usually only […]

DiagnoCure partner files prostate test with FDA

DiagnoCure partner files prostate test with FDA

September 21, 2010 by · Leave a Comment 

Tweet DiagnoCure’s (TSX:CUR) corporate partner has filed a premarket approvalapplication with the FDA for the Progensa PCA3 assay, a new molecular test that may help determine the need for repeat biopsies in men suspected of having prostate cancer. DiagnoCure holds the worldwide rights to the PCA3 biomarker and in 2003, it granted an exclusive sub-license […]

Next Page »

Google+